Cargando…

Chronic Heart Failure: Diagnosis and Management beyond LVEF Classification

Detalles Bibliográficos
Autores principales:	Triposkiadis, Filippos, Starling, Randall C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951412/ https://www.ncbi.nlm.nih.gov/pubmed/35330043 http://dx.doi.org/10.3390/jcm11061718

Ejemplares similares

The Sympathetic Nervous System in Hypertensive Heart Failure with Preserved LVEF
por: Triposkiadis, Filippos, et al.
Publicado: (2023)

Heart Failure
por: Giamouzis, Gregory, et al.
Publicado: (2011)

A Holistic View of Advanced Heart Failure
por: Triposkiadis, Filippos, et al.
Publicado: (2022)

Heart Failure 2013
por: Giamouzis, Gregory, et al.
Publicado: (2013)

Heart Failure 2012
por: Giamouzis, Gregory, et al.
Publicado: (2012)

Diabetes Mellitus and Heart Failure
por: Triposkiadis, Filippos, et al.
Publicado: (2021)

Red Blood Cell Distribution Width in Heart Failure: Pathophysiology, Prognostic Role, Controversies and Dilemmas
por: Xanthopoulos, Andrew, et al.
Publicado: (2022)

Both intermuscular fat and LVEF decline promote heart failure symptoms in cancer survivors
por: Reding, Kerryn W., et al.
Publicado: (2021)

Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF
por: Rubattu, Speranza, et al.
Publicado: (2017)

The Neurohormonal Overactivity Syndrome in Heart Failure
por: Xanthopoulos, Andrew, et al.
Publicado: (2023)

Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece
por: Athanasakis, Kostas, et al.
Publicado: (2016)

Heart failure with preserved ejection fraction: A distinct heart failure phenotype?
por: Triposkiadis, Filippos, et al.
Publicado: (2022)

Machine learning-aided detection of heart failure (LVEF ≤ 49%) by using ballistocardiography and respiratory effort signals
por: Feng, Shen, et al.
Publicado: (2023)

Heart Failure in Patients with Chronic Kidney Disease
por: Xanthopoulos, Andrew, et al.
Publicado: (2023)

Human Gut Microbiota in Heart Failure: Trying to Unmask an Emerging Organ
por: Paraskevaidis, Ioannis, et al.
Publicado: (2023)

Reshaping Treatment of Heart Failure with Preserved Ejection Fraction
por: Karamichalakis, Nikolaos, et al.
Publicado: (2022)

Hypertensive Heart Failure
por: Triposkiadis, Filippos, et al.
Publicado: (2023)

Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications
por: Triposkiadis, Filippos, et al.
Publicado: (2020)

The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications
por: Triposkiadis, Filippos, et al.
Publicado: (2021)

Cognitive Impairment in Heart Failure
por: Dardiotis, Efthimios, et al.
Publicado: (2012)

Editorial: Novel and emerging therapies in heart failure
por: Giamouzis, Grigorios, et al.
Publicado: (2023)

DNA Damage in Chronic Heart Failure: Consequences Beyond those in the Heart
por: Corrêa, Camila Renata, et al.
Publicado: (2020)

Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost?
por: Xanthopoulos, Andrew, et al.
Publicado: (2022)

Levosimendan benefits critically ill patients with decompensated heart failure assessed with plasma B-type natriuretic peptide (BNP) and LVEF
por: McLean, AS, et al.
Publicado: (2003)

Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline
por: Julián, María Teresa, et al.
Publicado: (2020)

Effects of Different LVEF Assessed by Echocardiography and CMR on the Diagnosis and Therapeutic Decisions of Cardiovascular Diseases
por: Zhao, Lei, et al.
Publicado: (2020)

Telemonitoring in Chronic Heart Failure: A Systematic Review
por: Giamouzis, Gregory, et al.
Publicado: (2012)

Advances and Challenges in Diagnosis and Management of Heart Failure
por: Sullivan, Ryan D., et al.
Publicado: (2022)

Medical Treatment in Heart Failure with Reduced Ejection Fraction: A Proposed Algorithm Based on the Patient’s Electrolytes and Congestion Status
por: Paraskevaidis, Ioannis, et al.
Publicado: (2023)

Predictive values of heart rate variability, deceleration and acceleration capacity of heart rate in post‐infarction patients with LVEF ≥35%
por: Liu, Xiang, et al.
Publicado: (2020)

Myocardial Recovery
por: Chrysakis, Nikolaos, et al.
Publicado: (2023)

Clinical Relevance of the LVEDD and LVESD Trajectories in HF Patients With LVEF < 35%
por: Chen, Yu-Chen, et al.
Publicado: (2022)

Remote preconditioning in normal and hypertrophic rat hearts
por: Voucharas, Christos, et al.
Publicado: (2011)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

Optimizing Chronic Heart Failure Care Beyond Randomised Controlled Trials – What are the problem areas and potential solutions?
por: Iyngkaran, Pupalan
Publicado: (2016)

Investigation on left ventricular multi-directional deformation in patients of hypertension with different LVEF
por: Huang, Huimei, et al.
Publicado: (2017)

Contemporary Diagnosis and Management of Hypertrophic Cardiomyopathy: The Role of Echocardiography and Multimodality Imaging
por: Kitai, Takeshi, et al.
Publicado: (2022)

ACE2, the Counter-Regulatory Renin–Angiotensin System Axis and COVID-19 Severity
por: Triposkiadis, Filippos, et al.
Publicado: (2021)

Beyond lipid lowering: pleiotropic effects of statins in heart failure
por: Swenne, C. A.
Publicado: (2013)

Assessing physical activity with the wearable cardioverter defibrillator in patients with newly diagnosed heart failure
por: Iliodromitis, Konstantinos, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9d8dsv9dnu8fdel45aoq6o8pnf